+944.2%
RKLB vs GSK
+48.7%
+895.5%
-61.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.3% | +0.2% | -4.4% | -4.3% |
| 7D | 0.0% | -3.6% | +3.5% | +0.1% |
| 30D | -21.2% | -5.9% | -15.3% | -21.0% |
| 3M | -41.7% | -4.3% | -37.5% | -41.6% |
| 6M | -11.8% | -10.8% | -1.0% | -11.7% |
| YTD | -9.6% | +1.8% | -11.4% | -9.2% |
| 1Y | +34.1% | +23.5% | +10.6% | +34.4% |
| All | +944.2% | +48.7% | +895.5% | +931.3% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling